PT - JOURNAL ARTICLE AU - Singh, Samer AU - Diwaker, Amita AU - Singh, Rakesh K. TI - NUTRITIONAL IMMUNITY, ZINC SUFFICIENCY AND COVID-19 MORTALITY IN SOCIALLY SIMILAR EUROPEAN POPULATIONS AID - 10.1101/2020.11.04.20151290 DP - 2021 Jan 01 TA - medRxiv PG - 2020.11.04.20151290 4099 - http://medrxiv.org/content/early/2021/04/24/2020.11.04.20151290.short 4100 - http://medrxiv.org/content/early/2021/04/24/2020.11.04.20151290.full AB - The impact of Zinc (Zn) sufficiency/supplementation on COVID-19 mortality and infections remains unknown. During an infection, the levels of free Zinc are reduced as a part of ‘nutritional immunity’ to limit the growth and replication of pathogens and ensuing inflammatory damage. However, considering its key role in immune competence and the widespread deficiency in large sections of different populations (3-54%), prophylactic and therapeutic Zn supplementation has become part of routine prescription even without any evidence for its protective role in COVID-19. Expectedly, multiple trials are ascertaining the positive effect of Zn supplementation on COVID-19 when given in combination with standard of care treatments. However, the trials’ designs seem to lack the power to identify negative effects especially in the currently identified vulnerable groups, e.g., elderly, comorbid (contributing 9 out of 10 deaths; up to >8000-fold higher mortality). When we analyze the COVID-19 data from 23 socially similar European populations with supposedly comparable confounders (population: 522.47 million; experiencing up to >150 fold difference in death rates) and at the matching stage of the pandemic (12 March - 26 June 2020; 1st wave of infections), the populations’ Zn-sufficiency status is found consistently positively correlated with COVID-19 mortality (r(23): 0.7893–0.6849, p-value<0.0003) and infections [r(23):0.8084 to 0.5658; p-value<0.005]. The observed association is contrary to what would be expected if Zn sufficiency was being protective in COVID-19. Thus, controlled trials or retrospective analysis of the adverse event patients’ data seem warranted to correctly guide the practice of Zn supplementation in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been received for the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript/references provided.